Evidence map›Paper›PMID 34626953›Full record

ArticleTranslational oncology2021

Comparative mRNA/micro-RNA co-expression network drives melanomagenesis by promoting epithelial-mesenchymal transition and vasculogenic mimicry signaling.

WenFeng He, Gang Yang, Shuya Liu, Mazaher Maghsoudloo, Marzieh Dehghan Shasaltaneh, Parham Jabbarzadeh Kaboli, Cuiwei Zhang, JingHeng Zhang, Maliheh Entezari, Saber Imani and 1 more

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

WenFeng HeDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Gang YangDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China; Department of Oncology, Anyue Hospital of Traditional Chinese Medicine, Second Ziyang Hospital of Traditional Chinese Medicine, Ziyang, Sichuan, China.
Shuya LiuDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China; Department of Oncology, Chengdu Jinniu District People's Hospital, Chengdu, Sichuan, China.
Mazaher MaghsoudlooLaboratory of Systems Biology and Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran; Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Marzieh Dehghan ShasaltanehDepartment of Biology, Faculty of Science, University of Zanjan, Zanjan, Iran.
Parham Jabbarzadeh KaboliGraduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung, Taiwan.
Cuiwei ZhangDepartment of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
JingHeng ZhangOncology Department, Luzhou People's Hospital, Luzhou, Sichuan, China.
Maliheh EntezariDepartment of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Farhikhtegan Medical Convergence sciences Research Center, Farhikhtegan Hospital Tehran Medical sciences, Islamic Azad University, Tehran, Iran.
Saber ImaniDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Electronic address: saberimani@swmu.edu.cn.
QingLian WenDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. Electronic address: wql73115@hotmail.com.
Affiliated Hospital of Southwest Medical University · CNChina Medical University · TWFirst Affiliated Hospital of Sichuan Medical University · CNIslamic Azad University Medical Branch of Tehran · IRUniversity of Tehran · IRUniversity of Zanjan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to identify a novel disease-associated differentially co-expressed mRNA-microRNA (miRNA) that is associated with vasculogenic mimicry (VM) and epithelial-to-mesenchymal transition (EMT) network at different stages of melanoma. By applying weighted gene co-expression network analysis, we constructed a VM+EMT biological network with the available microarray dataset downloaded from a public database. Quantitative real-time PCR, immunohistochemical staining, and CD31-periodic acid solution dual staining were performed to confirm the expression of genes associated with EMT and VM formation in subjects with malignant melanoma (n = 18) and primary melanoma (n = 13) and in healthy subjects (n = 10). Our findings suggested that phosphatidylserine-specific phospholipase A1-alpha (PLA1A) and dermokine (DMKN) genes function as oncogenes that trigger VM and EMT processes during melanomagenesis on interaction with miR-370, miR-563, and miR-770-5p. PLA1A and DMKN genes can be considered potential VM+EMT network-based diagnostic biomarkers for distinguishing between melanoma patients. We postulate that a network with altered PLA1A/miR-563 and DMNK/miR-770-5p/miR-370 may contribute to melanomagenesis by triggering the EMT signaling pathway and VM formation. This study provides a potentially valuable approach for the early diagnosis and prognosis of melanoma progression.

Indexed as

BiomarkerEpithelial–mesenchymal transitionMelanomagenesismRNA/micro-RNA co-expressionVasculogenic mimicry

Identifiers

PMID34626953
PMCPMC8512639
OpenAlexW3205923978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.